HRP20210021T1 - Derivati pirazol[1,5-a]pirimidina kao inhibitori jak kinaze - Google Patents
Derivati pirazol[1,5-a]pirimidina kao inhibitori jak kinaze Download PDFInfo
- Publication number
- HRP20210021T1 HRP20210021T1 HRP20210021TT HRP20210021T HRP20210021T1 HR P20210021 T1 HRP20210021 T1 HR P20210021T1 HR P20210021T T HRP20210021T T HR P20210021TT HR P20210021 T HRP20210021 T HR P20210021T HR P20210021 T1 HRP20210021 T1 HR P20210021T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrimidine
- cyanopyridazin
- pyrazolo
- amino
- carboxamide
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- HDTXWUHMYZRQFF-LJQANCHMSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-methoxypyridin-2-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound COC1=CC=CC(=N1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N HDTXWUHMYZRQFF-LJQANCHMSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- JXSIEYYMYPREPS-GOSISDBHSA-N 2-(6-aminopyridin-3-yl)-7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1(C)CN(CC[C@H]1NC1=C(C=NC2=CC(=NN12)C1=CC=C(N)N=C1)C(N)=O)C1=CC=C(N=N1)C#N JXSIEYYMYPREPS-GOSISDBHSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- JTPSKPROJGIBDI-LJQANCHMSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(2-ethoxypyrimidin-5-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CCOC1=NC=C(C=N1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N JTPSKPROJGIBDI-LJQANCHMSA-N 0.000 claims 1
- LYLLCQWYSUYGGS-OAQYLSRUSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(2-fluoro-5-methoxyphenyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound COC1=CC(C2=NN3C(=C2)N=CC(C(N)=O)=C3N[C@@H]2CCN(CC2(C)C)C2=CC=C(N=N2)C#N)=C(F)C=C1 LYLLCQWYSUYGGS-OAQYLSRUSA-N 0.000 claims 1
- NAPIINLZOBSSIC-GOSISDBHSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(2-methoxypyrimidin-5-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound COC1=NC=C(C=N1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N NAPIINLZOBSSIC-GOSISDBHSA-N 0.000 claims 1
- YELDZETVZPUXHI-HXUWFJFHSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1=NC=CC(=C1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N YELDZETVZPUXHI-HXUWFJFHSA-N 0.000 claims 1
- BYUXOSCZSBDHCP-JOCHJYFZSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(2-morpholin-4-ylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1(C)CN(CC[C@H]1NC1=C(C=NC2=CC(=NN12)C1=CC(=NC=C1)N1CCOCC1)C(N)=O)C1=CC=C(N=N1)C#N BYUXOSCZSBDHCP-JOCHJYFZSA-N 0.000 claims 1
- SOMAZMKZPNEGTA-OAQYLSRUSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound COC1=CC=C(C=C1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N SOMAZMKZPNEGTA-OAQYLSRUSA-N 0.000 claims 1
- BADZFACFHKQQAM-HXUWFJFHSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-ethoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CCOC1=CC=C(C=N1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N BADZFACFHKQQAM-HXUWFJFHSA-N 0.000 claims 1
- JCQZAHAQZMHZIH-GOSISDBHSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1(C)CN(CC[C@H]1NC1=C(C=NC2=CC(=NN12)C1=CC=C(F)N=C1)C(N)=O)C1=CC=C(N=N1)C#N JCQZAHAQZMHZIH-GOSISDBHSA-N 0.000 claims 1
- PDCOCXXKCFPMBU-FSRHSHDFSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-methoxypyridin-2-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride Chemical compound Cl.C(#N)C1=CC=C(N=N1)N1CC([C@@H](CC1)NC1=C(C=NC=2N1N=C(C2)C2=NC(=CC=C2)OC)C(=O)N)(C)C PDCOCXXKCFPMBU-FSRHSHDFSA-N 0.000 claims 1
- QUZAOGVECIEWLE-LJQANCHMSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound COC1=CC=C(C=N1)C1=NN2C(=C1)N=CC(C(N)=O)=C2N[C@@H]1CCN(CC1(C)C)C1=CC=C(N=N1)C#N QUZAOGVECIEWLE-LJQANCHMSA-N 0.000 claims 1
- NYBFBMJGYKYPFD-JOCHJYFZSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-(6-morpholin-4-ylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1(C)CN(CC[C@H]1NC1=C(C=NC2=CC(=NN12)C1=CC=C(N=C1)N1CCOCC1)C(N)=O)C1=CC=C(N=N1)C#N NYBFBMJGYKYPFD-JOCHJYFZSA-N 0.000 claims 1
- LWEDGUAWGGCPNU-LJQANCHMSA-N 7-[[(4R)-1-(6-cyanopyridazin-3-yl)-3,3-dimethylpiperidin-4-yl]amino]-2-pyridin-3-ylpyrazolo[1,5-a]pyrimidine-6-carboxamide Chemical compound CC1(C)CN(CC[C@H]1NC1=C(C=NC2=CC(=NN12)C1=CC=CN=C1)C(N)=O)C1=CC=C(N=N1)C#N LWEDGUAWGGCPNU-LJQANCHMSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Claims (13)
1. Spoj opće formule (I)
[image]
pri čemu R1 predstavlja:
-fenil supstituiran sa jednim ili dva supstituenta odabranim iz grupe koja se sastoji od halogena i C1-C3 alkoksi;
ili
-6-člani heteroaril sa 1 ili 2 atoma dušika, koji je nesupstituiran ili supstituiran supstituentom odabranim iz grupe koja se sastoji od:
-NH2,
-halogena,
-alkila C1-C4,
-alkoksila C1-C3, i
-6-članog heterociklila koji sadrži 1 ili 2 heteroatoma odabrana iz grupe koja se sastoji od N i O;
ili njegova kisela adicijska sol.
2. Spoj prema patentnom zahtjevu 1, pri čemu R1 predstavlja fenil supstituiran sa jednim ili dva supstituenta odabranim iz grupe koja se sastoji od halogena i C1-C3 alkoksila.
3. Spoj prema patentnom zahtjevu 1, pri čemu R1 predstavlja 6-člani heteroaril sa 1 ili 2 atoma dušika, koji je nesupstituiran ili supstituiran supstituentom odabranim iz grupe koja se sastoji od:
-NH2,
-halogena,
-alkila C1-C4,
-alkoksila C1-C3, i
-6-članog heterociklila koji sadrži 1 ili 2 heteroatoma odabrana iz grupe koja se sastoji od N i O.
4. Spoj prema patentnom zahtjevu 3, pri čemu navedeni heteroaril je piridinil.
5. Spoj prema patentnom zahtjevu 3, pri čemu navedeni heteroaril je pirimidinil.
6. Spoj prema patentnom zahtjevu 4 ili 5, pri čemu je navedeni heteroaril supstituiran supstituentom odabranim iz grupe koja se sastoji od alkila C1-C4, alkoksila C1-C3 i 6-članog heterociklila koji sadrži 1 ili 2 heteroatoma odabrana iz grupe koja se sastoji od N i O.
7. Spoj prema patentnom zahtjevu 4, pri čemu je piridinil, posebno piridin-2-il, piridin-3-il ili piridin-4-il supstituiran C1-C3 alkoksilom.
8. Spoj prema patentnom zahtjevu 5, pri čemu je primidinil, posebno pirimidin-5-il, supstituiran C1-C3 alkoksilom.
9. Spoj prema patentnom zahtjevu 1, odabran iz grupe koja se sastoji od sljedećeg:
1) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(4-metoksifenil)pirazolo[1,5-a]pirimidin-6-karboksamida;
2) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(2-fluoro-5-metoksifenil)pirazolo[1,5-a]pirimidin-6-karboksamida;
3) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(piridin-3-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
4) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-metoksipiridin-3-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
5) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-etoksipiridin-3-il)pirazolo[1,5-a]piramidin-6-karboksamida;
6) (R)-2-(6-Aminopiridin-3-il)-7-((1-(6-cijanopiridazin-3-il)-3,3-dimetil-piperidin-4-il)amino)pirazolo[1,5-a]pirimidin-6-karboksamida;
7) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-morfolinopiridin-3-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
8) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(2-metoksipirimidin-5-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
9) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(2-etoksipirimidin-5-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
10) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-fluorpiridin-3-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
11) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-metoksipiridin-2-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
12) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(2-metilpiridin-4-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
13) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(2-morfolinopiridin-4-il)pirazolo[1,5-a]pirimidin-6-karboksamida;
14) (R)-7-((1-(6-Cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)-amino)-2-(6-metoksipiridin-2-il)pirazolo[1,5-a]piramidin-6-karboksamid hidroklorida.
10. Spoj prema patentnom zahtjevu 9, koji je (R)-7-((1-(6-cijanopiridazin-3-il)-3,3-dimetilpiperidin-4-il)amino)-2-(6-metoksipiridin-2-il)pirazolo[1,5-a]-piramidin-6-karboksamid ili njegova kisela adicijska sol.
11. Spoj prema bilo kom od patentnih zahtjeva 1 do 10 za primjenu kao lijek.
12. Spoj prema bilo kom od patentnih zahtjeva 1 do 10 za primjenu u postupku liječenja kroničnih upalnih ili autoimunih bolesti.
13. Farmaceutska kompozicija koja kao aktivni sastojak sadrži spoj kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL421576A PL233595B1 (pl) | 2017-05-12 | 2017-05-12 | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
| EP18723532.0A EP3621966B1 (en) | 2017-05-12 | 2018-05-10 | Pyrazole[1,5-a]pyrimidine derivatives as kinase jak inhibitors |
| PCT/EP2018/062164 WO2018206739A1 (en) | 2017-05-12 | 2018-05-10 | Pyrazole[1,5-a]pyrimidine derivatives as kinase jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210021T1 true HRP20210021T1 (hr) | 2021-02-19 |
Family
ID=64104351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210021TT HRP20210021T1 (hr) | 2017-05-12 | 2021-01-07 | Derivati pirazol[1,5-a]pirimidina kao inhibitori jak kinaze |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11072619B2 (hr) |
| EP (1) | EP3621966B1 (hr) |
| JP (1) | JP7157084B2 (hr) |
| KR (1) | KR102533519B1 (hr) |
| CN (1) | CN110612302B (hr) |
| AU (1) | AU2018265457B2 (hr) |
| BR (1) | BR112019023480A2 (hr) |
| CA (1) | CA3059829A1 (hr) |
| DK (1) | DK3621966T3 (hr) |
| EA (1) | EA038273B1 (hr) |
| ES (1) | ES2845230T3 (hr) |
| HR (1) | HRP20210021T1 (hr) |
| HU (1) | HUE052997T2 (hr) |
| MX (1) | MX2019013462A (hr) |
| PL (2) | PL233595B1 (hr) |
| PT (1) | PT3621966T (hr) |
| SI (1) | SI3621966T1 (hr) |
| WO (1) | WO2018206739A1 (hr) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101088922B1 (ko) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘 |
| ATE428422T1 (de) | 2004-02-05 | 2009-05-15 | Schering Corp | Piperidin-derivate als ccr3-antagonisten |
| PT1812440E (pt) * | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| WO2008084861A1 (ja) | 2007-01-12 | 2008-07-17 | Astellas Pharma Inc. | 縮合ピリジン化合物 |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| CN102596959A (zh) | 2009-07-31 | 2012-07-18 | 拜奥克里斯特制药公司 | 吡咯并[1,2-b]哒嗪衍生物作为janus激酶抑制剂 |
| KR20120102601A (ko) * | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
| US8921368B2 (en) | 2011-03-17 | 2014-12-30 | Bristol-Myers Squibb Company | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| TW201249846A (en) * | 2011-03-17 | 2012-12-16 | Bristol Myers Squibb Co | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2666353T3 (es) * | 2012-09-06 | 2018-05-04 | Bristol-Myers Squibb Company | Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias |
| PL407081A1 (pl) | 2014-02-05 | 2015-08-17 | Celon Pharma Spółka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2 |
-
2017
- 2017-05-12 PL PL421576A patent/PL233595B1/pl unknown
-
2018
- 2018-05-10 EA EA201992632A patent/EA038273B1/ru unknown
- 2018-05-10 WO PCT/EP2018/062164 patent/WO2018206739A1/en active Application Filing
- 2018-05-10 CN CN201880030939.9A patent/CN110612302B/zh active Active
- 2018-05-10 SI SI201830179T patent/SI3621966T1/sl unknown
- 2018-05-10 MX MX2019013462A patent/MX2019013462A/es unknown
- 2018-05-10 KR KR1020197034120A patent/KR102533519B1/ko active IP Right Grant
- 2018-05-10 CA CA3059829A patent/CA3059829A1/en active Pending
- 2018-05-10 DK DK18723532.0T patent/DK3621966T3/da active
- 2018-05-10 AU AU2018265457A patent/AU2018265457B2/en active Active
- 2018-05-10 US US16/609,891 patent/US11072619B2/en active Active
- 2018-05-10 PL PL18723532T patent/PL3621966T3/pl unknown
- 2018-05-10 JP JP2019562296A patent/JP7157084B2/ja active Active
- 2018-05-10 HU HUE18723532A patent/HUE052997T2/hu unknown
- 2018-05-10 PT PT187235320T patent/PT3621966T/pt unknown
- 2018-05-10 EP EP18723532.0A patent/EP3621966B1/en active Active
- 2018-05-10 ES ES18723532T patent/ES2845230T3/es active Active
- 2018-05-10 BR BR112019023480-2A patent/BR112019023480A2/pt unknown
-
2021
- 2021-01-07 HR HRP20210021TT patent/HRP20210021T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019023480A2 (pt) | 2020-06-30 |
| JP7157084B2 (ja) | 2022-10-19 |
| SI3621966T1 (sl) | 2021-04-30 |
| WO2018206739A1 (en) | 2018-11-15 |
| EP3621966B1 (en) | 2020-11-18 |
| EA201992632A1 (ru) | 2020-04-13 |
| EA038273B1 (ru) | 2021-08-03 |
| DK3621966T3 (da) | 2021-01-18 |
| CN110612302A (zh) | 2019-12-24 |
| ES2845230T3 (es) | 2021-07-26 |
| HUE052997T2 (hu) | 2021-06-28 |
| PL3621966T3 (pl) | 2021-06-28 |
| EP3621966A1 (en) | 2020-03-18 |
| PL421576A1 (pl) | 2018-11-19 |
| PL233595B1 (pl) | 2019-11-29 |
| MX2019013462A (es) | 2020-01-15 |
| CA3059829A1 (en) | 2018-11-15 |
| US11072619B2 (en) | 2021-07-27 |
| AU2018265457A1 (en) | 2019-10-24 |
| KR20200005562A (ko) | 2020-01-15 |
| US20200199128A1 (en) | 2020-06-25 |
| CN110612302B (zh) | 2022-06-14 |
| KR102533519B1 (ko) | 2023-05-17 |
| PT3621966T (pt) | 2021-01-20 |
| JP2020519631A (ja) | 2020-07-02 |
| AU2018265457B2 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| HRP20200342T1 (hr) | Derivati dihidroimidazopirazinona korisni u liječenju raka | |
| HRP20180538T1 (hr) | Inhibitori za erk i postupci njihove uporabe | |
| HRP20170162T1 (hr) | HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE | |
| HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
| HRP20171998T1 (hr) | Spojevi i sastavi za liječenje parazitnih bolesti | |
| HRP20210940T1 (hr) | Spoj arilazola i sredstvo za suzbijanje štetočina | |
| MD4735B1 (ro) | Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK) | |
| HRP20211855T1 (hr) | Inhibitori dnk-pk | |
| HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| FI3786162T3 (fi) | Bipyratsolijohdannaisia jak-inhibiittoreina | |
| RU2022100782A (ru) | Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью | |
| BR112015016327A8 (pt) | inibidores da atividade de pirazol quinase substituídos por policíclicos e seu uso | |
| EA201591906A1 (ru) | Производные мочевины, полезные в качестве ингибиторов киназы | |
| BR112018069530A2 (pt) | composições de forma de dosagem que compreendem um inibidor da tirosina quinase de bruton | |
| JP2016540803A5 (hr) | ||
| PH12018500827A1 (en) | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors | |
| PH12020551624A1 (en) | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | |
| EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| HRP20221277T1 (hr) | Kondenzirani heterociklični spoj | |
| RU2018143284A (ru) | Некоторые ингибиторы протеинкиназы | |
| HRP20210508T1 (hr) | Biciklički derivati piridina, pirazina i pirimidina kao inhibitori pi3k beta |